prikaz prve stranice dokumenta Ishod neoadjuvantne terapije kod pacijenata s karcinomom dojke
  Download
PDF 400.97 KB
master's thesis
Ishod neoadjuvantne terapije kod pacijenata s karcinomom dojke
Zagreb: University of Zagreb, School of Medicine, 2024. urn:nbn:hr:105:607772
Augustinov, Mirta
University of Zagreb
School of Medicine
Department of Pathology

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Augustinov, M. (2024). Ishod neoadjuvantne terapije kod pacijenata s karcinomom dojke (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:607772

Augustinov, Mirta. "Ishod neoadjuvantne terapije kod pacijenata s karcinomom dojke." Master's thesis, University of Zagreb, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:105:607772

Augustinov, Mirta. "Ishod neoadjuvantne terapije kod pacijenata s karcinomom dojke." Master's thesis, University of Zagreb, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:105:607772

Augustinov, M. (2024). 'Ishod neoadjuvantne terapije kod pacijenata s karcinomom dojke', Master's thesis, University of Zagreb, School of Medicine, accessed 14 January 2025, https://urn.nsk.hr/urn:nbn:hr:105:607772

Augustinov M. Ishod neoadjuvantne terapije kod pacijenata s karcinomom dojke [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2024 [cited 2025 January 14] Available at: https://urn.nsk.hr/urn:nbn:hr:105:607772

M. Augustinov, "Ishod neoadjuvantne terapije kod pacijenata s karcinomom dojke", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2024. Available at: https://urn.nsk.hr/urn:nbn:hr:105:607772

Metadata
TitleIshod neoadjuvantne terapije kod pacijenata s karcinomom dojke
Title (english)Outcome of neoadjuvant therapy in breast cancer patients
AuthorMirta Augustinov
MentorSanda Šitić (mentor)
Committee memberLjubica Vazdar (predsjednik povjerenstva)
Committee memberLovorka Batelja Vuletić (član povjerenstva)
Committee memberSanda Šitić (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Pathology)
Zagreb
Defense date and country2024-09-11, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract
Cilj: Cilj rada je usporediti patohistološki odgovor na neoadjuvantnu terapiju u dvije skupine pacijentica s ranim rakom dojke, HER2 negativne luminalne u odnosu na HER2 pozitivne, luminalne i neluminalne. Metode: U istraživanje je uključeno 42 pacijentice s različitim podtipovima karcinoma dojke: luminalni HER2 negativan te HER2 pozitivan, uključujući neluminalni i luminalni podtip. Kod svih pacijentica je neoadjuvantna terapija (NAT) u potpunosti provedena. Statistička analiza podataka provedena je Shapiro-Wilkovim testom. Rezultati: Rezultati su pokazali da prije provedene NAT u skupini od 22 pacijentice s HER2 pozitivnim karcinomom dojke, 8 je bilo u stadiju 2a, 9 u stadiju 2b, a 3 u stadiju 3a. Nakon provedene NAT, sve pacijentice u ovoj skupini su se našle u stadijima 0 i 1a, od čega je gotovo dvije trećine (N=13; 59,09%) postiglo stadij 0. Sve HER2 pozitivne pacijentice na NAT su odgovorile s RCB-0 (potpunim patološkim odgovorom) ili RCB-I. Statistički značajno smanjenje površine tumora zabilježeno je u obje ispitivane skupine nakon provedene terapije. Zaključak: Pacijentice s HER2 pozitivnim rakom dojke pokazale su bolji odgovor na neoadjuvantnu terapiju u usporedbi s pacijenticama s HER2 negativnim rakom dojke te je biološka terapija dualnom HER2 blokadom; trastuzumabom i pertuzumabom rezultirala značajno većom stopom potpunog patološkog odgovora.
Abstract (english)
Objective: The aim of this study is to compare the response to neoadjuvant therapy in a group of patients with HER2 negative luminal breast cancer with a group of patients with HER2 positive breast cancer, including luminal and non luminal. Methods: The study included 42 patients with different breast cancer subtypes: luminal B HER2 negative breast cancer and HER2-positive breast cancer, including both non-luminal and luminal B subtypes, who completed neoadjuvant therapy (NAT). Statistical data analysis was performed using the Shapiro-Wilk test. Results: The results showed that prior to NAT, out of the 22 patients in the HER2-positive group, 8 were in stage 2a, 9 in stage 2b, and 3 in stage 3a. After NAT, all patients in this group were in stage 0 or 1a, with almost two-thirds (N=13; 59.09%) achieving stage 0. All HER2-positive patients responded to NAT with either RCB-0 (pathological complete response) or RCB-I. A statistically significant reduction in tumor size was observed in both examined groups after therapy. Conclusion: Patients with HER2 positive breast cancer showed a better response to neoadjuvant therapy compared to HER2 negative patients. Targeted therapy with dual HER2 blockade, using trastuzumab and pertuzumab, resulted in significantly improved outcomes, as evidenced by a pathological complete response.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:607772
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-09-09 11:33:31